Gemzar

(Gemcitabine)

ApprovedSmall molecule

Gemcitabine is a chemotherapy drug used to treat certain types of cancer, including pancreatic cancer, breast cancer, and lung cancer, by slowing or stopping the growth of cancer cells.[2] Gemzar is currently approved and in use across 139 indications[4].[1]

Gemzar is one of 1466 small molecule programs targeting Ovarian Cancer. It is currently in Approved.

139

Indications

1,566

Total Trials

Active Trials

1,465

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Ovarian CancerUnknown status

Pancreatic Ductal AdenocarcinomaTerminated

Biliary Tract CancerCompleted

Urothelial CarcinomaUnknown status

Metastatic Colorectal CancerCompleted

Solid TumorTerminated

Pancreas CancerCompleted

Advanced Biliary Tract CarcinomaNot yet recruiting

Biliary Tract NeoplasmApproved

Biliary Tract DiseaseApproved

Ovarian CancerPhase 3

Unknown status

Pancreatic Ductal AdenocarcinomaPhase 3

Terminated

Biliary Tract CancerPhase 3

Completed

Urothelial CarcinomaPhase 3

Unknown status

Metastatic Colorectal CancerPhase 2

Completed

Solid TumorPhase 2

Terminated

Pancreas CancerPhase 2

Completed

Advanced Biliary Tract CarcinomaPhase 2

Not yet recruiting

Biliary Tract NeoplasmApproved

Approved

Biliary Tract DiseaseApproved

Approved

Showing 10 of 139 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Approved

87 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Acupan

YYonsei University

Preclinical

1 6

Nubain

AAultman Health Foundation

Preclinical

1 7

Paracetamol

GSK

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 10

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT05498220

Phase 2Recruiting

Lung Cancer

NCT04966663

Phase 2Active, not recruiting

Ovarian Cancer

NCT04274426

Phase 2Active, not recruiting

Nasopharyngeal Carcinoma

NCT04517214

Q1 2027

Phase 3Active, not recruiting

Triple-Negative Breast Cancer

NCT05382286

Q2 2027

Phase 2Active, not recruiting

Breast Cancer

NCT06531447

Clinical

Trials by Indication[1]

Pancreatic Cancer35 trials

Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I

Completed·JJoseph J. Cullen·Phase 1·NCT01852890·16 enrolled

Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT01964534·114 enrolled

Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer

Active, not recruiting·DDo-Youn Oh·Phase 2·NCT03572400·71 enrolled

Show 32 more trials

GTX-RT in Borderline Resectable Pancreatic Cancer

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT01754623·9 enrolled

A Study of Locally Advanced Pancreatic Cancer

Unknown status·NNational Health Research Institutes, Taiwan·Phase 2·NCT01063192·73 enrolled

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

Completed· Ipsen logo

Ipsen·Phase 3·NCT04083235·770 enrolled

A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Completed· Roche logo

Roche·Phase 2·NCT00652366·467 enrolled

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Withdrawn·IImmunityBio, Inc.·Phase 2·NCT03563144

Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer

Completed·NNYU Langone Health·Phase 2·NCT00696696·45 enrolled

Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00057876·74 enrolled

First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT03693677·288 enrolled

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT02155088·15 enrolled

Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

Completed·KKangLaiTe USA·Phase 2·NCT00733850·85 enrolled

Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.

Completed·HHerlev Hospital·Phase 1/2·NCT04247165·55 enrolled

Dose-Escalation Study of Intensity-Modulated Radiotherapy(IMRT)in Patients With Unresectable Pancreatic Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT00593866·50 enrolled

A Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane in Pancreatic Cancer

Completed·—·Phase 1/2·NCT01506973·119 enrolled

Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer

Completed·—·Phase 1·NCT01908478·34 enrolled

A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer

Recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07079228·602 enrolled

Safety and Efficacy Study of P276-00 in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

Completed·PPiramal Enterprises Limited·Phase 1/2·NCT00898287·23 enrolled

Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

Unknown status·CCrystalGenomics, Inc.·Phase 1/2·NCT02737228·24 enrolled

Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer

Completed·UUniversity Hospital, Toulouse·Phase 2·NCT02806687·68 enrolled

A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients

Unknown status·SSamsung Pharmaceutical Co., Ltd.·Phase 3·NCT02854072·148 enrolled

An Observational Study of Erlotinib Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer

Completed· Roche logo

Roche··NCT01782690·338 enrolled

RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer

Unknown status·RRise Biopharmaceuticals, Inc.·Phase 1·NCT04338763·48 enrolled

First-Line Gemcitabine Chemotherapy With Our Without Sunitinib In Advanced or Metastatic Pancreatic Cancer

Completed·CCentral European Society for Anticancer Drug Research·Phase 2·NCT00673504·105 enrolled

Gemcitabine and Capecitabine in Patients With Advanced Pancreatic Cancer

Completed·SSwedish Medical Center·Phase 1·NCT00316420·20 enrolled

A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Recruiting· Amgen logo

Amgen·Phase 1·NCT06360354·350 enrolled

Study With Gemcitabine and RTA 402 for Patients With Unresectable Pancreatic Cancer

Terminated· Biogen logo

Biogen·Phase 1·NCT00529113·33 enrolled

Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

Unknown status·FFudan University·Phase 3·NCT04835064·600 enrolled

Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer

Unknown status·AAzienda Ospedaliero, Universitaria Pisana·Phase 3·NCT02355119·310 enrolled

Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer

Terminated·MMassachusetts General Hospital·Phase 1·NCT00593008·5 enrolled

YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer

Not yet recruiting·SShanghai YingLi Pharmaceutical Co. Ltd.·Phase 1/2·NCT06662669·120 enrolled

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Completed·HHalozyme Therapeutics·Phase 2·NCT01839487·279 enrolled

Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients with Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT01821612·23 enrolled

Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer

Not yet recruiting·JJinling Hospital, China·Phase 2·NCT06177522·30 enrolled

Breast Cancer16 trials

Organoid-based Functional Precision Therapy for Advanced Breast Cancer

Recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT06102824·252 enrolled

Gemcitabine/Vinorelbine Versus Gemcitabine/Cisplatin Versus Gemcitabine/Capecitabine in Metastatic Breast Cancer

Completed·LLudwig-Maximilians - University of Munich·Phase 2·NCT00480597·141 enrolled

Docetaxel vs. Docetaxel-Gemcitabine in Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191243·237 enrolled

Show 13 more trials

A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer

Terminated·HHoosier Cancer Research Network··NCT00235235·80 enrolled

Guided Treatment Based on Mini-PDX in Metastatic Triple Negative Breast Cancer

Unknown status·FFudan University·Phase 2·NCT04745975·100 enrolled

Nadunolimab in Combination with Gemcitabine Plus Carboplatin in Patients with Advanced Triple Negative Breast Cancer.

Active, not recruiting·CCantargia AB·Phase 1/2·NCT05181462·117 enrolled

A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191373·66 enrolled

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

Completed· Gilead logo

Gilead·Phase 3·NCT03901339·543 enrolled

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

Completed·NNektar Therapeutics·Phase 3·NCT02915744·178 enrolled

Vinorelbine and Gemcitabine Versus Capecitabine in Pretreated Metastatic Breast Cancer

Completed·HHellenic Oncology Research Group·Phase 3·NCT00431106·144 enrolled

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

Active, not recruiting·TThe National Center of Oncology, Azerbaijan·Phase 2·NCT06531447·200 enrolled

Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00623233·52 enrolled

A Trial Of Gemcitabine Plus Paclitaxel And Gemcitabine Plus Docetaxel In Metastatic Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191672·120 enrolled

RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure

Not yet recruiting·FFudan University·Phase 2/3·NCT07366840·268 enrolled

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT02755272·87 enrolled

Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT00128856·46 enrolled

Non-Small Cell Lung Cancer15 trials

Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer

Completed·SStanford University·Phase 2·NCT00323869·48 enrolled

Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)

Completed·NNational Taiwan University Hospital·Phase 2·NCT00154739·86 enrolled

Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer

Terminated·NNewLink Genetics Corporation·Phase 2/3·NCT01774578·135 enrolled

Show 12 more trials

A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Terminated· Roche logo

Roche·Phase 2·NCT00940875·54 enrolled

Trial Of AG-013736, Cisplatin, And Gemcitabine For Patients With Squamous Non-Small Cell Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00735904·38 enrolled

The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer

Completed·FFudan University·Phase 2·NCT01797913·70 enrolled

Study Of The Effect Of CP-751,871 In Combination With Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer

Withdrawn· Pfizer logo

Pfizer·Phase 3·NCT00907504

Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02142738·305 enrolled

Study of Paclitaxel, Carboplatin, and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 3·NCT00193362·200 enrolled

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02477826·2,747 enrolled

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Completed· Roche logo

Roche·Phase 3·NCT02409342·572 enrolled

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01160744·280 enrolled

A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)

Terminated· Roche logo

Roche·Phase 3·NCT02409355·8 enrolled

Iscar for Second Line Treatment of Advanced Non-Small Cell Lung Cancer

Completed·KKentuckiana Cancer Institute·N/A·NCT00283478·20 enrolled

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Terminated·NNorthwestern University·Phase 1/2·NCT00004093·36 enrolled

Pancreatic Adenocarcinoma11 trials

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Completed·—·Phase 2·NCT02723331·48 enrolled

A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)

Completed·CClovis Oncology, Inc.·Phase 2·NCT01124786·367 enrolled

Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma

Completed·—·Phase 2·NCT01360593·35 enrolled

Show 8 more trials

The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.

Withdrawn·YYale University·Phase 2·NCT04045730

Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)

Unknown status·NNovoCure GmbH·Phase 1/2·NCT01971281·40 enrolled

Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02109445·3 enrolled

Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma

Completed·NNational Taiwan University Hospital·Phase 1/2·NCT00154791·45 enrolled

A Randomized Phase 2 Study of ARQ 197 Versus Gemcitabine in Treatment-Naïve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00558207·43 enrolled

Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT01431794·23 enrolled

A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma

Completed·IIRCCS San Raffaele·Phase 1/2·NCT01730222·137 enrolled

Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Completed·OOncolytics Biotech·Phase 1·NCT02620423·11 enrolled

Lymphoma10 trials

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Recruiting· Regeneron logo

Regeneron·Phase 3·NCT06230224·216 enrolled

ChiCGB vs BEAM in High-risk or R/R Lymphomas

Unknown status·SSichuan University·Phase 3·NCT05466318·306 enrolled

A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Recruiting·SSecuraBio·Phase 3·NCT06522737·124 enrolled

Show 7 more trials

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

Completed· Roche logo

Roche·Phase 1·NCT01359696·40 enrolled

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Not yet recruiting·IImmuneOnco Biopharmaceuticals (Shanghai) Inc.·Phase 3·NCT06465446·202 enrolled

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Terminated· Gilead logo

Gilead·Phase 1/2·NCT02953509·178 enrolled

GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma

Terminated·AAHS Cancer Control Alberta·Phase 1/2·NCT02295722·100 enrolled

Study of Lacutamab in Peripheral T-cell Lymphoma

Recruiting·TThe Lymphoma Academic Research Organisation·Phase 2·NCT04984837·56 enrolled

Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy

Completed·UUniversity College, London·Phase 2·NCT01679119·129 enrolled

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

Completed·WWashington University School of Medicine·Phase 1·NCT02181218·24 enrolled

66 more indications

Bladder Cancer9 trials

Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer

Completed· Sanofi logo

Sanofi·Phase 3·NCT00625664·337 enrolled

Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00585689·29 enrolled

Neoadjuvant Chemo (Gemcitabine and Cisplatin) With Radical Cystectomy or Radiotherapy in Patients With Bladder Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00490880·2 enrolled

Show 6 more trials

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01916109·4 enrolled

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT04241185·520 enrolled

A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function

Completed·DDr Anders Ullén·Phase 2·NCT02665039·62 enrolled

Drug Screening Using IMD in Bladder Cancer

Unknown status·—·Phase 1·NCT06204614·18 enrolled

Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer

Terminated· Eisai logo

Eisai·Phase 1/2·NCT01126749·92 enrolled

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT02177695·237 enrolled

Ovarian Cancer6 trials

Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval

Unknown status·NNational Cancer Institute, Naples·Phase 3·NCT00657878·215 enrolled

A Study LY2228820 for Recurrent Ovarian Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT01663857·118 enrolled

European Trial on Enhanced DNA Repair Inhibition in Ovarian Cancer

Completed·UUniversitaire Ziekenhuizen KU Leuven·Phase 2·NCT03783949·122 enrolled

Show 3 more trials

Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Active, not recruiting·AAGO Research GmbH·Phase 2·NCT04274426·136 enrolled

Treatment of Paclitaxel Plus Carboplatin Followed by Gemcitabine Plus Carboplatin for Patients With Epithelial Ovarian Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00490711·7 enrolled

Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT03467178·119 enrolled

Gemcitabine5 trials

HAI Abraxane With Gemcitabine and Bevacizumab

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01057264·78 enrolled

Adjuvant Effect of Chloroquine on Gemcitabine

Completed·UUniversity of Zurich·Phase 1·NCT01777477·9 enrolled

CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas

Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT00540579·23 enrolled

Show 2 more trials

Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA

Recruiting·SShanghai Zhongshan Hospital··NCT07291063·50 enrolled

ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC

Completed·FFudan University·Phase 2·NCT01810367·84 enrolled

Biliary Tract Cancer5 trials

Adjuvant Chemotherapy for Biliary Tract Cancer After Curative Resection

Unknown status·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT03779035·460 enrolled

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

Not yet recruiting·WWashington University School of Medicine·Phase 1·NCT07107750·48 enrolled

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06001658·27 enrolled

Show 2 more trials

GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer

Unknown status·—·Phase 2·NCT01859728·48 enrolled

Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer

Completed·—·Phase 2·NCT00123825·30 enrolled

Small Cell Lung Cancer4 trials

A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191490·162 enrolled

TORCH: A Study of Tarceva or Chemotherapy for the Treatment of Advanced Non Small Cell Lung Cancer

Completed·NNational Cancer Institute, Naples·Phase 3·NCT00349219·760 enrolled

Multicenter Phase 2 Trial Evaluating Cisplatin-Gemcitabine With Concomitant Thoracic Radiotherapy for Treatment of Inoperable Stage III Non Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00192036·49 enrolled

Show 1 more trial

A Study Comparing Two Different Chemotherapy Types in Chinese Patients With Advanced Non Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT01005680·256 enrolled

Lung Cancer4 trials

A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00870870·64 enrolled

Using ctDNA to Determine Therapies for Lung Cancer

Recruiting·UUniversity Health Network, Toronto·Phase 2·NCT04966663·66 enrolled

Trial of Perioperative Chemotherapy (Gemcitabine and Cisplatin) and Adjuvant Chemoradiotherapy (With Weekly Low Dose Gemcitabine) in Patients With Lung Cancer With Positive Nodes

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00490659·13 enrolled

Show 1 more trial

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

Unknown status·—·Phase 2·NCT00150657·45 enrolled

Adenocarcinoma3 trials

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Terminated·PPoint Therapeutics·Phase 2·NCT00116389·60 enrolled

Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas

Completed·AAmer Zureikat·Phase 1/2·NCT01128296·35 enrolled

Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00191503·30 enrolled

Cholangiocarcinoma3 trials

A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma

Withdrawn·UUniversity of Louisville·Phase 3·NCT03081039

Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation

Terminated·SStanford University·Phase 2·NCT01151761·2 enrolled

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Terminated·QQED Therapeutics, a BridgeBio company·Phase 3·NCT03773302·48 enrolled

Advanced Solid Tumors3 trials

A Safety Study in Participants With Advanced Solid Tumors

Terminated· Eli Lilly logo

Eli Lilly·Phase 1·NCT01284335·234 enrolled

Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors

Completed·TTraws Pharma, Inc.·Phase 1·NCT01165905·10 enrolled

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Completed· Bayer logo

Bayer·Phase 1·NCT03102320·173 enrolled

Pancreatic Ductal Adenocarcinoma3 trials

A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Terminated·HHalozyme Therapeutics·Phase 3·NCT02715804·492 enrolled

Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Terminated· Novartis logo

Novartis·Phase 2·NCT04390763·164 enrolled

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruiting·WWashington University School of Medicine·Phase 1/2·NCT06904378·61 enrolled

Metastatic Urothelial Cancer3 trials

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Active, not recruiting· Astellas logo

Astellas·Phase 3·NCT04223856·886 enrolled

A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.

Completed·IInstitut Claudius Regaud·Phase 2/3·NCT02240017·46 enrolled

9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer

Recruiting·MMabwell (Shanghai) Bioscience Co., Ltd.·Phase 3·NCT06592326·460 enrolled

Cancer of the Pancreas3 trials

Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00005926·50 enrolled

A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the Pancreas

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001431·20 enrolled

Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00020345

Advanced Cancer2 trials

Phase 1 Study of PI3 (Phosphatidylinositol-3)-Kinase Inhibitor Copanlisib With Gemcitabine or Cisplatin Plus Gemcitabine in Patients With Advanced Cancer

Completed· Bayer logo

Bayer·Phase 1·NCT01460537·50 enrolled

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Terminated·WWestern Regional Medical Center·Phase 1/2·NCT02331251·81 enrolled

Patients With Advanced Solid Tumors2 trials

Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors

Completed·TTheriva Biologics SL·Phase 1·NCT02045602·42 enrolled

A Study of QLS31905 Combination Chemotherapy as First-Line Treatment in Patients With Advanced Solid Tumors

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 1/2·NCT06041035·115 enrolled

Nasopharyngeal Carcinoma2 trials

Combination of Gemcitabine and Carboplatin in Metastatic or Recurrent Nasopharyngeal Carcinoma

Completed·MMinistry of Health, Malaysia·Phase 2·NCT00697905·18 enrolled

Comparing Chemotherapy With/Without Toripalimab For Primary Metastatic Nasopharyngeal Carcinoma

Active, not recruiting·FFudan University·Phase 2·NCT04517214·100 enrolled

Locally Advanced or Metastatic NSCLC2 trials

Pemetrexed Plus Gemcitabine for Patients With Locally Advanced or Metastatic NSCLC Who Have Not Had Previous Chemotherapy.

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00061464·48 enrolled

Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus the Cisplatin/Docetaxel/Bevacizumab Combination in Locally Advanced or Metastatic NSCLC

Completed·HHellenic Oncology Research Group·Phase 2·NCT00620971·77 enrolled

Diffuse Large B-Cell Lymphoma2 trials

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Terminated· Pfizer logo

Pfizer·Phase 3·NCT02951156·29 enrolled

Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Active, not recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT05498220·5 enrolled

Chemotherapy2 trials

Chemotherapy and G-CSF for Mobilization

Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT03442673·137 enrolled

A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours

Unknown status·Ee-Therapeutics PLC·Phase 1·NCT02423239·112 enrolled

First Line Therapy2 trials

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

Not yet recruiting·SSun Yat-sen University·Phase 2/3·NCT04890522·622 enrolled

Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 3·NCT03629925·357 enrolled

Hepatocellular Carcinoma2 trials

Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma

Completed·MMassachusetts General Hospital·Phase 2·NCT00142467·33 enrolled

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Withdrawn·AAlbert Koong·Phase 3·NCT01327521

Safety and Efficacy1 trial

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

Completed· Roche logo

Roche·Phase 1·NCT02715531·243 enrolled

Pancreas Cancer1 trial

A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer

Unknown status·AAHS Cancer Control Alberta·Phase 3·NCT01586611·175 enrolled

Metastatic Solid Tumors1 trial

C14 Study in Oncology Patients With Advanced and/or Metastatic Solid Tumors

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01296568·3 enrolled

Relapsed/Refractory1 trial

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Completed·—·Phase 1/2·NCT03052933·28 enrolled

Synovial Sarcoma1 trial

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Terminated· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT04145700·23 enrolled

Triple-Negative Breast Cancer1 trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

Active, not recruiting· Gilead logo

Gilead·Phase 3·NCT05382286·443 enrolled

Newly Diagnosed1 trial

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Terminated·IIGM Biosciences, Inc.·Phase 1·NCT04553692·272 enrolled

Relapsed or Refractory1 trial

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL

Active, not recruiting·TThe Lymphoma Academic Research Organisation·Phase 3·NCT03593018·86 enrolled

Advanced Soft-tissue Sarcoma1 trial

Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)

Recruiting·AAsociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas·Phase 2·NCT06114004·88 enrolled

Preoperative1 trial

Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Early Stages NSCLC

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191126·263 enrolled

Advanced/Metastatic Cancer1 trial

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT02857270·210 enrolled

Pancreatic1 trial

Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours

Unknown status·PPD Dr. med. Volker Heinemann·Phase 2·NCT01728818·119 enrolled

Cervical Carcinoma1 trial

Intensity Modulated Radiation Therapy With Cisplatin and Gemcitabine to Treat Locally Advanced Cervical Carcinoma

Completed·UUniversity of California, San Diego·Phase 1·NCT01554410·35 enrolled

Locally-advanced Rectal Cancer1 trial

Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer

Unknown status·KKing Faisal Specialist Hospital & Research Center·Phase 2·NCT02919878·25 enrolled

Advanced Malignant Solid Tumors1 trial

Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors

Not yet recruiting· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06446388·360 enrolled

Primary Peritoneal Cancer1 trial

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00191607·162 enrolled

Sarcoma1 trial

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

Completed·MMorphotek·Phase 2·NCT01574716·209 enrolled

Pancreatic Carcinoma1 trial

A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

Completed·UUNICANCER·Phase 3·NCT02539537·171 enrolled

Solid Tumor Cancers1 trial

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00678132·23 enrolled

Overall Survival1 trial

Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint

Terminated· Amgen logo

Amgen·Phase 2·NCT00613730·3 enrolled

Fallopian Tube Cancer1 trial

A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed· Roche logo

Roche·Phase 2·NCT00096993·131 enrolled

Metastatic Head and Neck Cancer1 trial

Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00248560·36 enrolled

Soft Tissue Sarcoma1 trial

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT06370871

Malignant Pleural Mesothelioma1 trial

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

Active, not recruiting·FFerring Ventures Limited·Phase 3·NCT03710876·53 enrolled

Carcinoma of Unknown Primary1 trial

Combination of Carboplatin, Gemcitabine, and Capecitabine in Patients With Carcinoma of Unknown Primary Site

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00148135

Randomized Controlled Trial1 trial

Randomized Controlled Trial of Gemcitabine Combined With 125I Brachytherapy

Completed·HHuazhong University of Science and Technology·Phase 3·NCT00644618·120 enrolled

HER2-positive Advanced Solid Tumors1 trial

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Unknown status·SSUNHO（China）BioPharmaceutical CO., Ltd.·Phase 1/2·NCT04934514·97 enrolled

Transplantation1 trial

Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos

Unknown status·UUniversity of Pisa··NCT03668418·120 enrolled

Biliary Cancer1 trial

Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting·UUNICANCER·Phase 3·NCT05615818·800 enrolled

Glioma1 trial

Gemcitabine in Newly-Diagnosed Diffuse Midline Glioma

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT04051047

Solid Tumors1 trial

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Recruiting·VVasgene Therapeutics, Inc·Phase 2/3·NCT06493552·700 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma

Withdrawn·GGeorgetown University·Phase 2·NCT06017297

Elderly Patients1 trial

Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC

Terminated·HHellenic Oncology Research Group·Phase 3·NCT00442026·106 enrolled

First-line1 trial

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Completed· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 3·NCT02576574·1,214 enrolled

Renal Cell Carcinoma1 trial

Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma

Completed·UUniversity of Pittsburgh·Phase 2·NCT00630409·5 enrolled

Non-squamous NSCLC1 trial

Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab

Completed·AAktion Bronchialkarzinom e.V.·Phase 2·NCT00536640·224 enrolled

Periampullary Cancer1 trial

Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer

Completed·LLund University··NCT03724994·201 enrolled

Urothelial Carcinoma1 trial

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder

Active, not recruiting·—·Phase 1/2·NCT02202772·51 enrolled

Mantle Cell Lymphoma1 trial

Study of CEP-9722 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma

Completed·CCephalon·Phase 1·NCT01345357·24 enrolled

Metastatic1 trial

Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA

Completed·PPancreatic Cancer Research Team·Phase 1/2·NCT01893801·25 enrolled

Advanced Cancers1 trial

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Completed·TTrishula Therapeutics, Inc.·Phase 1·NCT03884556·56 enrolled

PTCL1 trial

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Recruiting·DDizal Pharmaceuticals·Phase 3·NCT07234162·218 enrolled

Lenalidomide1 trial

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00179751·50 enrolled

Nab-paclitaxel1 trial

Scheduling Nab-paclitaxel With Gemcitabine

Completed·CCCTU- Cancer Theme·Phase 2·NCT03529175·146 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Withdrawn·DDaiichi Pharmaceuticals·Phase 1·NCT00072228

Transitional Cell Carcinoma1 trial

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Withdrawn·OOncolytics Biotech·Phase 1·NCT02723838

Regulatory

FDA Approval Timeline[5]

May 15, 1996

GEMZAR

NDA NDA020509

Aug 4, 2011

GEMCITABINE HYDROCHLORIDE

NDA NDA200795

Aug 3, 2017

GEMCITABINE HYDROCHLORIDE

NDA NDA209604

Jul 16, 2018

INFUGEM

NDA NDA208313

Jun 27, 2025

AVGEMSI

NDA NDA219920

Sep 9, 2025

INLEXZO

NDA NDA219683

Sources

References

[1]
ClinicalTrials.gov — 1566 trial records for Gemcitabine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Gemzar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Gemcitabine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Gemcitabine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA219683). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Gemzar. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Polymerase (alpha/delta/epsilon) Inhibitor; Ribonucleoside-Diphosphate Reductase RR1 Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Johnson & Johnson

Patent Landscape[6]

Patent Cliff

Jun 28, 2030

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12403086Jun 28, 2030

12576253Dec 17, 2030

8679094Apr 15, 2032

9241948Jul 1, 2033

10729823Aug 19, 2034

2 more patents

12447241Aug 19, 2034

12636300Nov 6, 2038